Lilly (Eli) cash flow statement
In fiscal 2025, Lilly (Eli)'s operations generated $16.81bn of cash; it spent $7.84bn on capital projects, leaving free cash flow of $8.97bn. It returned $5.38bn in dividends and $4.11bn through buybacks.
Cash flow statement
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 4.3 | 6.9 | 7.2 | 5.3 | 5.7 | 4.5 | 3.0 | 4.9 | 5.6 | 5.5 | 4.8 | 6.5 | 7.4 | 7.6 | 4.2 | 8.8 | 16.8 | 30.6 |
| Depreciation and amortisation | 1.3 | 1.3 | 1.4 | 1.5 | 1.4 | 1.4 | 1.4 | 1.5 | 1.6 | 1.6 | 1.2 | 1.3 | 1.5 | 1.5 | 1.5 | 1.8 | 2.0 | 2.2 |
| Stock-based pay | 0.4 | 0.2 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | 0.6 | 0.6 | 0.6 | 0.7 |
| Capital spending | 0.8 | 0.7 | 0.7 | 0.9 | 1.0 | 1.2 | 1.1 | 1.0 | 1.1 | 1.2 | 1.0 | 1.4 | 1.3 | 1.9 | 3.4 | 5.1 | 7.8 | 11.0 |
| Free cash flow | 3.6 | 6.2 | 6.6 | 4.4 | 4.7 | 3.3 | 1.9 | 3.8 | 4.5 | 4.3 | 3.8 | 5.1 | 6.1 | 5.7 | 0.8 | 3.8 | 9.0 | 19.7 |
| Free cash flow after stock pay | 3.2 | 5.9 | 6.4 | 4.3 | 4.6 | 3.1 | 1.7 | 3.6 | 4.3 | 4.0 | 3.5 | 4.8 | 5.7 | 5.4 | 0.2 | 3.1 | 8.3 | 19.0 |
| Dividends paid | 2.2 | 2.2 | 2.2 | 2.2 | 2.1 | 2.1 | 2.1 | 2.2 | 2.2 | 2.3 | 2.4 | 2.7 | 3.1 | 3.5 | 4.1 | 4.7 | 5.4 | 6.0 |
| Share buybacks | — | 0.0 | 0.0 | 0.7 | 1.7 | 0.8 | 0.7 | 0.6 | 0.3 | 4.2 | 4.4 | 0.5 | 1.3 | 1.5 | 0.8 | 2.5 | 4.1 | 5.8 |
| Quarter | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 | 2026 Q3Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 2.5 | 1.7 | 3.1 | 8.8 | 3.2 | 5.3 | 10.7 | 11.4 |
| Depreciation and amortisation | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.5 | 0.5 | 0.5 |
| Stock-based pay | 0.1 | 0.2 | 0.2 | 0.2 | 0.1 | 0.2 | 0.2 | 0.2 |
| Capital spending | 1.5 | 1.5 | 1.7 | 2.1 | 2.5 | 2.3 | 2.9 | 3.2 |
| Free cash flow | 1.0 | 0.2 | 1.4 | 6.7 | 0.7 | 3.0 | 7.8 | 8.2 |
| Free cash flow after stock pay | 0.8 | 0.0 | 1.2 | 6.6 | 0.5 | 2.8 | 7.6 | 8.0 |
Compare with peers
- Johnson & Johnson cash flow
- Merck & Co. cash flow
- Pfizer cash flow
- Astrazeneca PLC cash flow
- Bristol Myers Squibb cash flow
Head to head: JNJ vs LLYLLY vs MRKLLY vs PFE
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies